HKSE - Delayed Quote HKD

CStone Pharmaceuticals (2616.HK)

Compare
2.710 +0.080 (+3.04%)
At close: 4:08:20 PM GMT+8
Currency in CNY All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
463,842.000
463,842.000
481,363.000
243,718.000
1,038,832.000
Cost of Revenue
159,547.000
159,547.000
202,985.000
106,832.000
241,421.000
Gross Profit
304,295.000
304,295.000
278,378.000
136,886.000
797,411.000
Operating Expense
884,140.000
884,140.000
1,181,475.000
1,930,359.000
1,861,832.000
Operating Income
-579,845.000
-579,845.000
-903,097.000
-1,793,473.000
-1,064,421.000
Net Non Operating Interest Income Expense
13,067.000
13,067.000
1,195.000
7,561.000
22,841.000
Pretax Income
-367,234.000
-367,234.000
-902,678.000
-1,920,100.000
-1,220,999.000
Net Income Common Stockholders
-367,234.000
-367,234.000
-902,678.000
-1,920,100.000
-1,220,999.000
Diluted NI Available to Com Stockholders
-367,234.000
-367,234.000
-902,678.000
-1,920,100.000
-1,220,999.000
Basic EPS
-0.29
-0.29
-0.77
-1.65
-1.17
Diluted EPS
-0.29
-0.29
-0.77
-1.65
-1.17
Basic Average Shares
1,263,073.000
1,263,073.000
1,172,839.000
1,165,209.000
1,046,032.000
Diluted Average Shares
1,263,073.000
1,263,073.000
1,172,839.000
1,165,209.000
1,046,032.000
Rent Expense Supplemental
3,513.000
3,513.000
3,069.000
2,475.000
3,160.000
Total Expenses
1,043,687.000
1,043,687.000
1,384,460.000
2,037,191.000
2,103,253.000
Net Income from Continuing & Discontinued Operation
-367,234.000
-367,234.000
-902,678.000
-1,920,100.000
-1,220,999.000
Normalized Income
-546,426.000
-546,426.000
-840,749.000
-1,854,995.000
-1,223,416.000
Interest Income
24,886.000
24,886.000
9,672.000
9,803.000
24,161.000
Interest Expense
11,819.000
11,819.000
8,477.000
2,242.000
1,320.000
Net Interest Income
13,067.000
13,067.000
1,195.000
7,561.000
22,841.000
EBIT
-355,415.000
-355,415.000
-894,201.000
-1,917,858.000
-1,219,679.000
EBITDA
-297,225.000
-297,225.000
-849,661.000
-1,895,197.000
-1,204,878.000
Reconciled Cost of Revenue
159,547.000
159,547.000
202,985.000
106,832.000
241,421.000
Reconciled Depreciation
58,190.000
58,190.000
44,540.000
22,661.000
14,801.000
Net Income from Continuing Operation Net Minority Interest
-367,234.000
-367,234.000
-902,678.000
-1,920,100.000
-1,220,999.000
Total Unusual Items Excluding Goodwill
179,192.000
179,192.000
-61,929.000
-65,105.000
2,417.000
Total Unusual Items
179,192.000
179,192.000
-61,929.000
-65,105.000
2,417.000
Normalized EBITDA
-476,417.000
-476,417.000
-787,732.000
-1,830,092.000
-1,207,295.000
12/31/2020 - 2/26/2019

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

1672.HK ASCLETIS-B
2.170
+0.93%
 
0ITA.BE Satellos Bioscience Inc
0.6550
+2.34%
 
2171.HK CARsgen Therapeutics Holdings Limited
9.650
-0.31%
 
6628.HK Transcenta Holding Limited
0.610
0.00%
 
1228.HK CANBRIDGE-B
0.152
-1.94%
 
6978.HK Immunotech Biopharm Ltd
2.550
-7.27%
 
1167.HK JACOBIO-B
1.310
-5.07%
 
2197.HK Clover Biopharmaceuticals, Ltd.
0.260
-3.70%
 
2105.HK Laekna, Inc.
10.840
-8.75%
 
ANL Adlai Nortye Ltd.
2.3600
+3.51%